McKesson Corporation | McKesson | wholesalers | off-label or unapproved promotion of medical products | 2021 | MULTI-AG | $8,001,000,000 |
AmerisourceBergen Corporation | Cencora Inc. | wholesalers | off-label or unapproved promotion of medical products | 2021 | MULTI-AG | $6,510,000,000 |
Cardinal Health Inc. | Cardinal Health | wholesalers | off-label or unapproved promotion of medical products | 2021 | MULTI-AG | $6,489,000,000 |
Walgreens | Walgreens Boots Alliance | retailing | off-label or unapproved promotion of medical products | 2022 | MULTI-AG | $5,700,000,000 |
Johnson & Johnson | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2021 | MULTI-AG | $5,000,000,000 |
CVS | CVS Health | retailing | off-label or unapproved promotion of medical products | 2022 | MULTI-AG | $5,000,000,000 |
Teva Pharmaceuticals | Teva Pharmaceutical Industries | pharmaceuticals | off-label or unapproved promotion of medical products | 2022 | MULTI-AG | $4,250,000,000 |
Walmart Stores | Walmart | retailing | off-label or unapproved promotion of medical products | 2022 | MULTI-AG | $3,100,000,000 |
GlaxoSmithKline LLC | GSK plc | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | FDA | $3,000,000,000 |
Allergan | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2022 | MULTI-AG | $2,370,000,000 |
Pfizer Inc. | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2009 | FDA | $2,300,000,000 |
Johnson & Johnson | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | FDA | $2,200,000,000 |
Mallinckrodt | Mallinckrodt | pharmaceuticals | Controlled Substances Act violation | 2020 | MULTI-AG | $1,600,000,000 |
Abbott Laboratories Inc. | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | FDA | $1,500,000,000 |
Eli Lilly and Company | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2009 | FDA | $1,415,000,000 |
Kroger | Kroger | retailing | off-label or unapproved promotion of medical products | 2023 | MULTI-AG | $1,370,000,000 |
Kroger | Kroger | retailing | off-label or unapproved promotion of medical products | 2024 | MULTI-AG | $1,370,000,000 |
Reckitt Benckiser Group plc | Reckitt Benckiser | household and personal care products | Controlled Substances Act violation | 2019 | USAO | $1,347,000,000 |
Merck, Sharp & Dohme | Merck | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | FDA | $950,000,000 |
Amgen Inc. | Amgen | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | FDA | $762,000,000 |
Serono, S.A. | Merck KGaA (EMD) | pharmaceuticals | off-label or unapproved promotion of medical products | 2005 | FDA | $704,000,000 |
Walgreens | Walgreens Boots Alliance | retailing | off-label or unapproved promotion of medical products | 2022 | FL-AG | $680,000,000 |
McKinsey & Co. Inc. | McKinsey | business services | Controlled Substances Act violation | 2024 | DOJ_CIVIL | $650,000,000 |
Amgen Inc. | Amgen | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $612,000,000 |
Allergan Inc. | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $600,000,000 |
McKinsey & Company | McKinsey | business services | off-label or unapproved promotion of medical products | 2021 | MULTI-AG | $573,000,000 |
Johnson & Johnson | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $541,000,000 |
AstraZeneca LP | AstraZeneca | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $520,000,000 |
Bristol-Myers Squibb Company | Bristol-Myers Squibb | pharmaceuticals | off-label or unapproved promotion of medical products | 2007 | DOJ_CIVIL | $515,000,000 |
Google Inc. | Alphabet Inc. | information technology | off-label or unapproved promotion of medical products | 2011 | FDA | $500,000,000 |
Wyeth Pharmaceuticals Inc. | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | FDA | $490,900,000 |
CVS Health Corporation and CVS Pharmacy, Inc. | CVS Health | retailing | off-label or unapproved promotion of medical products | 2022 | FL-AG | $484,000,000 |
GlaxoSmithKline | GSK plc | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $477,792,391 |
Endo International plc | Endo International | pharmaceuticals | off-label or unapproved promotion of medical products | 2022 | MULTI-AG | $450,000,000 |
Schering-Plough Corporation | Merck | pharmaceuticals | off-label or unapproved promotion of medical products | 2006 | USAO | $435,000,000 |
Warner-Lambert | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2004 | FDA | $430,000,000 |
Cephalon Inc | Teva Pharmaceutical Industries | pharmaceuticals | off-label or unapproved promotion of medical products | 2008 | FDA | $425,000,000 |
Novartis Pharmaceuticals Corporation | Novartis | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $422,500,000 |
Janssen Pharmaceuticals, Inc. | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | USAO | $410,000,000 |
Eli Lilly and Company | Eli Lilly | pharmaceuticals | off-label or unapproved promotion of medical products | 2009 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $361,828,456 |
Publicis Health | | | off-label or unapproved promotion of medical products | 2024 | MULTI-AG | $350,000,000 |
Abbott Laboratories | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $339,148,643 |
Walgreens | Walgreens Boots Alliance | retailing | off-label or unapproved promotion of medical products | 2023 | MI-AG | $338,000,000 |
Teva Pharmaceuticals, Ltd. | Teva Pharmaceutical Industries | pharmaceuticals | off-label or unapproved promotion of medical products | 2022 | NY-AG | $313,343,793 |
Indivior plc | Indivior PLC | pharmaceuticals | off-label or unapproved promotion of medical products | 2021 | MULTI-AG | $300,000,000 |
Walgreens | Walgreens Boots Alliance | retailing | off-label or unapproved promotion of medical products | 2023 | NV-AG | $285,000,000 |
Teva Pharmaceutical Industries | Teva Pharmaceutical Industries | pharmaceuticals | off-label or unapproved promotion of medical products | 2022 | FL-AG | $278,826,499 |
Amneal Pharmaceuticals | Amneal Pharmaceuticals | pharmaceuticals | off-label or unapproved promotion of medical products | 2024 | MULTI-AG | $272,500,000 |
Purdue Pharma | Purdue Pharma | pharmaceuticals | Controlled Substances Act violation | 2019 | OK-AG | $270,000,000 |
Serono Inc. | Merck KGaA (EMD) | pharmaceuticals | off-label or unapproved promotion of medical products | 2005 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $262,000,000 |
Wyeth Pharmaceuticals, Inc. | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2013 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $257,400,000 |
Walgreens | Walgreens Boots Alliance | retailing | off-label or unapproved promotion of medical products | 2023 | CA-SFCA | $229,610,000 |
Teva Pharmaceutical Industries Ltd. | Teva Pharmaceutical Industries | pharmaceuticals | off-label or unapproved promotion of medical products | 2022 | TX-AG | $225,000,000 |
AstraZeneca Pharmaceuticals LP | AstraZeneca | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $218,092,993 |
Walmart Inc. | Walmart | retailing | off-label or unapproved promotion of medical products | 2022 | FL-AG | $215,000,000 |
McKinsey & Co. | McKinsey | business services | off-label or unapproved promotion of medical products | 2024 | private lawsuit-federal | $207,000,000 |
Elan Corporation PLC | Perrigo | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $203,000,000 |
Merck Sharp & Dohme Corp. | Merck | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $201,975,000 |
Reckitt Benckiser Group | Reckitt Benckiser | household and personal care products | Controlled Substances Act violation | 2019 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $200,000,000 |
Allergan Finance LLC | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2021 | NY-AG | $200,000,000 |
Endo Health Solutions Inc. | Endo International | pharmaceuticals | off-label or unapproved promotion of medical products | 2014 | FDA | $192,700,000 |
Warner-Lambert | Pfizer | pharmaceuticals | off-label or unapproved promotion of medical products | 2004 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $190,000,000 |
Janssen Pharmaceuticals, Inc. | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | $181,000,000 |
Endo Health Solution | Endo International | pharmaceuticals | off-label or unapproved promotion of medical products | 2014 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $173,000,000 |
McKesson Corp. | McKesson | wholesalers | off-label or unapproved promotion of medical products | 2022 | WA-AG | $172,666,667 |
Cardinal Health, Inc. | Cardinal Health | wholesalers | off-label or unapproved promotion of medical products | 2022 | WA-AG | $172,666,667 |
AmerisourceBergen Corp. | Cencora Inc. | wholesalers | off-label or unapproved promotion of medical products | 2022 | WA-AG | $172,666,667 |
Forest Pharmaceuticals Inc. | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | FDA | $164,000,000 |
Johnson & Johnson | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | TX-AG | $158,000,000 |
Providence | Providence | healthcare services | healthcare price transparency violation | 2024 | WA-AG | $157,800,000 |
Cardinal Health | Cardinal Health | wholesalers | off-label or unapproved promotion of medical products | 2024 | private lawsuit-state | $152,500,000 |
McKesson Corporation | McKesson | wholesalers | Controlled Substances Act violation | 2017 | DEA | $150,000,000 |
Hikma Pharmaceuticals | Hikma Pharmaceuticals | pharmaceuticals | off-label or unapproved promotion of medical products | 2024 | MULTI-AG | $150,000,000 |
Johnson & Johnson | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2024 | WA-AG | $149,500,000 |
Allergan Ltd. et al. | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2022 | FL-AG | $134,200,000 |
AmerisourceBergen | Cencora Inc. | wholesalers | off-label or unapproved promotion of medical products | 2022 | WV-AG | $133,333,333 |
McKesson Corp. | McKesson | wholesalers | off-label or unapproved promotion of medical products | 2022 | WV-AG | $133,333,333 |
Cardinal Health Inc. | Cardinal Health | wholesalers | off-label or unapproved promotion of medical products | 2022 | WV-AG | $133,333,333 |
Warner Chilcott PLC | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2015 | FDA | $125,000,000 |
Cephalon Inc. | Teva Pharmaceutical Industries | pharmaceuticals | off-label or unapproved promotion of medical products | 2008 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $116,000,000 |
Cardinal Health | Cardinal Health | wholesalers | off-label or unapproved promotion of medical products | 2024 | AL-AG | $110,000,000 |
Cencora | Cencora Inc. | wholesalers | off-label or unapproved promotion of medical products | 2024 | AL-AG | $110,000,000 |
Walgreens Boots Alliance, Inc. | Walgreens Boots Alliance | retailing | off-label or unapproved promotion of medical products | 2023 | KY-AG | $102,000,000 |
Janssen Pharmaceuticals | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2022 | WV-AG | $99,000,000 |
Boehringer Ingelheim Pharmaceuticals Inc. | Boehringer Ingelheim | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | FDA | $95,000,000 |
Boehringer-Ingelheim Pharmaceuticals, Inc. | Boehringer Ingelheim | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $95,000,000 |
Schering-Plough Corporation | Merck | pharmaceuticals | off-label or unapproved promotion of medical products | 2006 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $91,602,000 |
Novartis Pharmaceuticals Corporation | Novartis | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $88,258,694 |
Indivior | Indivior PLC | pharmaceuticals | off-label or unapproved promotion of medical products | 2024 | MULTI-AG | $86,000,000 |
Scios Inc. | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2011 | FDA | $85,000,000 |
Teva Pharmaceuticals | Teva Pharmaceutical Industries | pharmaceuticals | Controlled Substances Act violation | 2019 | OK-AG | $85,000,000 |
Teva Pharmaceutical Industries | Teva Pharmaceutical Industries | pharmaceuticals | off-label or unapproved promotion of medical products | 2022 | WV-AG | $83,000,000 |
Ortho-McNeil Pharmaceutical LLC | Johnson & Johnson | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $81,000,000 |
Walgreens Corporation | Walgreens Boots Alliance | retailing | Controlled Substances Act violation | 2013 | DEA | $80,000,000 |
Allergan | AbbVie | pharmaceuticals | off-label or unapproved promotion of medical products | 2022 | WV-AG | $78,000,000 |
CVS Pharmacy, Inc | CVS Health | retailing | Controlled Substances Act violation | 2010 | DEA | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $77,600,000 |
CVS Pharmacy Inc. | CVS Health | retailing | Controlled Substances Act violation | 2010 | USAO | $77,600,000 |
SB Medical Inc. and TC Medical Group | | | off-label or unapproved promotion of medical products | 2015 | USAO | $75,000,000 |
Walgreens | Walgreens Boots Alliance | retailing | off-label or unapproved promotion of medical products | 2024 | MD-AG | $74,763,583 |
Novartis Vaccines & Diagnostics Inc. and Novartis Pharmaceuticals Corporation | Novartis | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $72,500,000 |
Teva Pharmaceuticals, Inc. | Teva Pharmaceutical Industries | pharmaceuticals | off-label or unapproved promotion of medical products | 2023 | KY-AG | $71,477,474 |